Stem Cells and Cancer

ISBN-13: 9781603279321 / Angielski / Twarda / 2009 / 346 str.

Rebecca G. Bagley; Beverly A. Teicher

Opis

Significance of Stem Cells to Tumor Development Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease. This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize side populations.' Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic ver

Recenzje

From the reviews: "This book ... covers topics ranging from prostate cancer stem cells to targeting brain cancer stem cells in the clinic. ... The book is written for a broad audience of basic science and clinical researchers interested in developmental biology and cancer cell biology. It will appeal to those interested in the promise of bioengineering using tissue-specific adult stem cells. ... I enjoyed the wide diversity of topics, large readable font, and beautiful color plates. ... The book is comprehensive yet readable." (Bruce A. Fenderson, Doody's Review Service, December, 2009)

Spis treści

Table of Contents Introduction – Cancer Stem Cells vs. Normal Stem Cells Rebecca Bagley, MS, Genzyme Corporation Chapter 1: Stem Cell Microenvironment – Hematopoietic Stem Cells Linheng Li, PhD, Stowers Institute for Medical Research Tannishtha Reya, PhD, Duke University Medical Center David Scadden, MD, Center for Regenerative Medicine, Mass General Hospital Sean Morrison, PhD, University of Michigan Medical School Chapter 2: Tumor Niche/Microenvironment – Mesenchymal Stem Cells Paul Simmons, PhD, University of Texas Health Science Center Ajeeta Dash, PhD, Genzyme Corporation Chapter 3: Cancer Stem Cells – Brain Tumors Peter Dirks, PhD, MD, University of Toronto Hospital for Sick Children Jeremey Rich, MD, Duke University Medical Center Nobuko Uchida, PhD, Stem Cells, Inc. Sheila Singh, MD, University of Toronto Hospital for Sick Children Chapter 4: Cancer Stem Cells – Breast Carcinoma Jane Visvader, PhD, Victorian Breast Cancer Research Consortium Max Wicha, MD, University of Michigan Comprehensive Cancer Center Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute Connie Eaves, PhD, British Columbia Cancer Research Centre Chapter 5: Cancer Stem Cells – Lung Cancers Carla Bender Kim, PhD, Children’s Hospital/Harvard University Joan Schiller, MD, Southwestern Medical School/Simmons Comprehensive Cancer Center Jaclyn Hung, PhD, British Columbia Cancer Research Centre Chapter 6: Cancer Stem Cells – Pancreatic Cancer Diane Simeone, MD, University of Michigan Medical Center Chapter 7: Cancer Stem Cells – Ovarian Paul Szotek, MD, Mass General Hospital, Harvard Medical School Chapter 8: Cancer Stem Cells – Colon Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute Hans Clevers,MD/PhD, Netherlands Institute for Developmental Biology Chapter 9: Cancer Stem Cells – Prostate Cancer Owen Witte/Susan Kasper Chapter 10: Epidermal Stem Cells Elaine Fuchs, PhD, Rockefeller University Fiona Watt, PhD, Cancer Resarch UK London, Cambridge Institute Chapter 11: Hematopoietic Stem Cells in Blood Cancers: Leukemia / Myeloma / Lymphoma Catriona Jamieson, MD/PhD, University of California Medical Center Daniel Tenen, MD, Beth Israel Deaconess Medical Center, Harvard Medical School Dominique Bonnet, PhD, London Research Institute Michael Becker, MD, University of Rochester Medical Center John Dick, PhD, Toronto General Research Institute Frederick Alt, PhD, Howard Hughes Medical Institute Michael Cleary, MD, Stanford University School of Medicine Irving Weissman, MD/PhD, Stanford University School of Medicine Craig Jordan, PhD, University of Rochester Medical Center Chapter 12: Epigenetic Control and Chromosomal Instability Laurie Jackson-Grusby, PhD, Children’s Hospital, Harvard Medical School Kornelia Polyak, MD/PhD, Dana-Farber Cancer Institute Bradley Bernstein, MD/PhD, Mass General Hospital, Harvard Medical School Stephen Baylin, MD, Johns Hopkins School of Medicine Chapter 13: Signaling Pathways Roeland Nusse, PhD, Stanford University Andreas Androutsellis-Theotokis, PhD, National Institute of Health Ivan Maillard, PhD, University of Pennsylvania School of Medicine Tannishtha Reya, PhD, Duke University Medical Center Linheng Li, Stowers, PhD, Institute for Medical Research Chapter 14: Targeting Cancer Stem Cells: A New Therapeutic Approach Tessa Holyoake, PhD, University of Glasgow D. Gary Gilliland, MD/PhD, Howard Hughes Medical Institute Jeffrey Molldrem, MD, M. D. Anderson Cancer Center Vera Donnenberg, PhD, McGowan Institute for

Blurb

Significance of Stem Cells to Tumor Development

Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease.

This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize ‘side populations.’ Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come.

Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies,  gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.

Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.